Caricamento...
Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma
Portal vein embolization (PVE) for hepatocellular carcinoma (HCC) was first introduced in 1986 and has been continuously developed throughout the years. Basically, PVE has been applied to expand the indication of liver resection for HCC patients of insufficient future liver remnant. Importantly, PVE...
Salvato in:
| Pubblicato in: | Ann Gastroenterol Surg |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164464/ https://ncbi.nlm.nih.gov/pubmed/34095718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ags3.12414 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|